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Abstract
Background: As the worldwide dietary pattern becomes more westernized, the metabolic syndrome is reaching epidemic
proportions. Lifestyle modifications including diet and exercise are recommended as first-line intervention for treating metabolic
syndrome. Previously, we reported that a modified Mediterranean-style, low glycemic load diet with soy protein and
phytosterols had a more favorable impact than the American Heart Association Step 1 diet on cardiovascular disease (CVD)
risk factors. Subsequently, we screened for phytochemicals with a history of safe use that were capable of increasing insulin
sensitivity through modulation of protein kinases, and identified hops rho iso-alpha acid and acacia proanthocyanidins. The
objective of this study was to investigate whether enhancement of a modified Mediterranean-style, low glycemic load diet (MED)
with specific phytochemicals (soy protein, phytosterols, rho  iso-alpha acids and proanthocyanidins; PED) could improve
cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia.
Methods: Forty-nine subjects with metabolic syndrome and hypercholesterolemia, aged 25–80, entered a randomized, 2-arm,
12-week intervention trial; 23 randomized to the MED arm; 26 to the PED arm. Forty-four subjects completed at least 8 weeks
[MED (n = 19); PED (n = 25)]. All subjects were instructed to follow the same aerobic exercise program. Three-day diet diaries
and 7-day exercise diaries were assessed at each visit. Fasting blood samples were collected at baseline, 8 and 12 weeks for
analysis.
Results: Both arms experienced equal weight loss (MED: -5.7 kg; PED: -5.9 kg). However, at 12 weeks, the PED arm
experienced greater reductions (P < 0.05) in cholesterol, non-HDL cholesterol, triglycerides (TG), cholesterol/HDL and TG/
HDL compared with the MED arm. Only the PED arm experienced increased HDL (P < 0.05) and decreased TG/HDL (P < 0.01),
and continued reduction in apo B/apo A-I from 8 to 12 weeks. Furthermore, 43% of PED subjects vs. only 22% of MED subjects
had net resolution of metabolic syndrome. The Framingham 10-year CVD risk score decreased by 5.6% in the PED arm (P <
0.01) and 2.9% in the MED arm (P < 0.05).
Conclusion:  These results demonstrate that specific phytochemical supplementation increased the effectiveness of the
modified Mediterranean-style low glycemic load dietary program on variables associated with metabolic syndrome and CVD.
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Background
Overconsumption of a maladaptive, westernized diet con-
sisting of foods that are calorie-dense, nutritionally-poor,
phytochemical-depleted, highly processed and rapidly
absorbable has been shown to increase systemic inflam-
mation and reduce insulin sensitivity [1-3]. With chronic
ingestion, this dietary pattern often results in metabolic
syndrome (MetS), a physiologic state encompassing a
cluster of metabolic abnormalities, including dyslipi-
demia, central obesity, hypertension, and glucose intoler-
ance. These are all independent risk factors for the
development of type 2 diabetes and/or cardiovascular dis-
ease (CVD) [4,5]. The NHANES 1999–2000 estimated the
prevalence of MetS in the US at an unadjusted 34.5% or
approximately 69 million persons [6]. As worldwide food
consumption patterns shift to the aforementioned dietary
pattern, MetS is becoming a significant burden in devel-
oping nations and global prevalence is growing [7,8].
It is widely viewed that MetS results from an increasing,
perpetual state of whole body insulin resistance, which is
strongly associated with dietary carbohydrate [9-11] and
saturated fat [12], leading to high serum triglycerides (TG)
and visceral adiposity [13-15]. Acute infusion of free fatty
acids leads to the accumulation of TG in skeletal muscle
and evokes whole body insulin resistance with the same
temporal pattern [16-19]. Metabolites of lipid metabo-
lism such as diacylglycerol have been shown to directly
induce insulin resistance by chronically activating protein
kinase C (PKC). PKC activation terminates insulin signal-
ing, preventing crucial tyrosine phosphorylation by the
insulin receptor, leading to impaired insulin signaling
[14]. MetS is also associated with a state of chronic inflam-
mation. Adipocyte leakage has recently been shown to
result in the recruitment of macrophages, which envelope
excess lipids, form foam cells, and release inflammatory
cytokines, setting up a state of systemic, chronic inflam-
mation [20,21]. These adipokines lead to the systemic
activation of several protein kinases involved in inflam-
matory signal transduction, including phosphoinositide-
3 kinase (PI3K), glycogen synthase kinase (GSK-3) and
PKC that singly or in concert cause insulin resistance in
skeletal muscle and adipose tissue [22-24]. Hence, thera-
pies which reduce circulating lipids and reduce systemic
inflammation have shown promise in the treatment of
insulin resistance and MetS.
Lifestyle modifications including diet and exercise are rec-
ommended as first-line intervention for treating insulin
resistance and MetS by the National Cholesterol Educa-
tion Program (NCEP) and American Heart Association
(AHA). The Mediterranean-style diet, high in plant foods
and monounsaturated fatty acids and low in processed
foods and refined carbohydrates, has been shown to
reduce CVD risk factors [25-28] and inflammatory burden
associated with MetS etiology [29]. Pharmacologic treat-
ment is considered appropriate if the individual is refrac-
tory to a lifestyle approach [30,31]. A recent review of the
literature reveals that both intensive lifestyle modifica-
tions and drugs such as rimonabant or rosiglitazone may
reduce the prevalence of MetS in 25 – 33% of patients
[32]. While new pharmacologic approaches to MetS are
under development [7], relying on drug therapy for an
epidemic caused by a maladaptive diet is not as rational as
realigning dietary habits [33]. These findings suggest that
new lifestyle modification approaches in the treatment of
MetS and its complications should be important public
health priorities.
Advancing knowledge in inflammation and insulin sign-
aling suggest that reversing the chronic imbalances of
these downstream kinases provides a promising and logi-
cal strategy for reducing insulin resistance and the meta-
bolic abnormalities of MetS. Inhibition of downstream
kinases could be accomplished by using pharmaceuticals
such as sunitinib and imatinib (multi-target protein
kinases drugs), approved to treat cancers but which may
also cause remission of diabetes [34]. However, several
dietary phytochemicals, such as genistein and curcumin,
have been shown to be protein kinase inhibitors [35,36].
A recent study showed that combining additional dietary
polyphenols with a Mediterranean diet could provide syn-
ergistic effects and positively impact postprandial dysme-
tabolism [33]. As such, an important aspect to consider in
dietary recommendations for MetS is the incorporation of
diverse, targeted biologically-active phytochemicals to
address the multiple underlying mechanisms of MetS. In
a previous study [37], we reported that the addition of soy
protein and phytosterols to a Mediterranean-style, low
glycemic load diet had a more favorable impact than the
AHA Step 1 diet on cholesterol/HDL and TG/HDL, blood
pressure (BP), and Framingham 10-year CVD risk score
for coronary heart disease in overweight, postmenopau-
sal, hypercholesterolemic women.
With the finding that soy protein and phytosterols plus a
Mediterranean-style diet could favorably affect the TG/
HDL, an indicator of MetS, we initiated a screening pro-
gram to identify additional structurally diverse phyto-
chemicals capable of increasing insulin sensitivity
through the modulation of downstream kinases. We
screened 203 botanical products in 3T3-L1 adipocytes and
identified novel substituted 1, 3-cyclopentadiones as well
as a number of proanthocyanidin extracts with adipogenic
and anti-inflammatory activity. One of the substituted 1,
3-cyclopentadiones was rho  iso-alpha acids (RIAA)
derived from hops (Humulus lupulus). RIAA have been
used as bitter flavoring agents in beer for decades. We
found RIAA dose dependently inhibited GSK-3, PI3K, and
PKCβ in cell free kinase assays (manuscript in prepara-Nutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
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tion). Another bioactive material identified by our screen
was the proanthocyanidin-rich extract (PAC) of Acacia
nilotica. In addition to inhibiting GSK-3, PI3K, and PKC, it
also inhibited IKKβ in a dose-dependent manner (manu-
script in preparation). At 5:1 (RIAA:PAC), the greatest effi-
cacy in reducing glucose and insulin in the db/db mouse
model was observed (manuscript in preparation). Fur-
thermore, in an unpublished human pilot study, MetS
subjects who consumed a combination of RIAA and PAC
showed greater lowering of fasting LDL, TG, and TG/HDL
than the placebo group.
The objective of this study was to investigate whether by
enhancing a modified Mediterranean-style, low glycemic
load diet with specific phytochemical supplementation
we could improve cardiometabolic outcomes in subjects
with MetS. Targeted supplementation included soy pro-
tein, phytosterols, hops RIAA and acacia PAC. The same
diet was used in both arms and incorporated a spectrum
of unprocessed, modified Mediterranean-style foods with
an overall glycemic load less than 65.
Methods
Subjects
Men and women between the ages of 25 to 80 years with
MetS and hypercholesterolemia were recruited into this
study. Inclusion criteria included body mass index (BMI)
≥ 27 kg/m2, TG ≥ 1.70 mmol/L and < 4.52 mmol/L, LDL
≥ 3.37 mmol/L, and at least 2 of the following 4 criteria:
(i) waist circumference > 88 cm (women) and > 102 cm
(men); (ii) HDL < 1.30 mmol/L (women), and < 1.04
mmol/L (men); (iii) BP ≥ 130/85 mm Hg and < 155/95
mm Hg or diagnosed hypertension on medication; and
(iv) fasting glucose ≥ 5.55 mmol/L and ≤ 7.00 mmol/L.
Initial screening of subjects' serum lipids and glucose was
performed using an in-office device (Cholestech LDX® Sys-
tem). Eligible subjects were further screened with com-
plete metabolic profile and complete blood count. Some
key exclusion criteria included involvement in a weight
loss program leading to 10% or greater body weight loss
over the preceding 6 weeks; use of blood glucose or cho-
lesterol lowering medications or supplements, corticoster-
oid use in the preceding 12 weeks; NSAID use ≥ 3 days/
week in the preceding 4 weeks; or a history of chronic ill-
ness. This study was approved by the Copernicus Group
Independent Review Board and was conducted based on
good clinical practice guidelines. Informed written con-
sent was obtained from each participant before enroll-
ment in the study.
Study design
This study was a randomized, 12-week, open-label, 2-arm
trial conducted at the Functional Medicine Research
Center in Gig Harbor, WA from June 15, 2006 through
November 20, 2006 (Fig. 1). Subjects who satisfied the
inclusion criteria were randomized to 1 of 2 arms using a
commercial software program (Microsoft Excel®  2003;
Microsoft); subjects were stratified by sex. Participants
from both arms were instructed to follow a modified Med-
iterranean-style, low glycemic load diet (MED) and were
provided with dietary guidelines, including a list of allow-
able foods, suggested serving sizes and recipes (see addi-
tional file 1: List of Permitted Foods and Beverages,
Serving Sizes and Recipe). Subjects were asked to consume
the diet until satisfied.
Modified Mediterranean-style low glycemic load diet (MED)
The rationale for defining this dietary program as "modi-
fied Mediterranean-style, low glycemic load" is that it
includes a variety of low glycemic phytochemically-rich
foods. Not all Mediterranean-style diets are low in glyc-
emic load [38], and not all low glycemic load diets are
phytochemically-diverse; thus, we chose to leverage the
benefits of both by combining them together.
Specifically, the diet used in this study is distinguishable
from the classic Mediterranean diet in that it is limited in
the number of servings of alcohol and, in particular,
whole grain. Alcohol intake was kept to a minimum: an
optional 1 glass of red wine (4 oz) daily for all subjects. In
the Mediterranean diet, several (typically 6 or more) serv-
ings of grain are often advocated; however, based on the
available literature and our experience with this dietary
program in the past decade, we decided to limit whole
grains to 1 serving daily. Riccardi et al. [38] suggested that
the standard Mediterranean diet may not be beneficial for
individuals with insulin resistance due to the high carbo-
hydrate content. Additionally, in our own use of this pro-
gram, we found that reducing grain intake lowers cravings
in many subjects. Moreover, Mediterranean-like food
items such as pizza and hard toasted bread have been
shown to have glycemic responses similar to white bread.
Thus, one of the primary stipulations for foods in this die-
tary program was to ensure that all items included were
low in glycemic load. The glycemic index of foods most
commonly eaten was ≤ 55, with occasional selection (no
more than 1 serving daily) from a small category of phy-
tochemical-rich vegetables with a moderate glycemic
index (55–70). This diet is also notable in that it omits all
forms of sweeteners (natural and synthetic) except low-
glycemic agave nectar syrup and stevia.
Phytochemical enriched diet (PED)
Subjects in the Phytochemical Enriched Diet (PED) arm
additionally received (i) a combination of soy protein and
plant sterols in a powdered beverage (2 servings/day, see
additional file 2: Macronutrient profile of the soy and
phytosterol-based powdered beverage) and (ii) a tablet
containing RIAA from Humulus lupulus L. (RIAA magne-
sium salt) and PAC from Acacia nilotica bark (1 tablet, 2Nutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
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times daily). Two daily servings of the powdered beverage
(UltraMeal Plus®, Metagenics Inc.) provided 30 g of non-
GMO soy protein (34 mg soy isoflavones) and 4 g of phy-
tosterols (at least 40% β-sitosterol). The tablet contained
150 mg RIAA and 30 mg PAC. At 2 daily, subjects ingested
a total of 300 mg RIAA and 60 mg PAC. Subjects were
instructed to return all unused beverage powder and tab-
lets, and the percentage of the amount consumed was cal-
culated to indicate compliance. Subjects in the MED arm
received neither the powdered beverage nor tablets. All
participants were counseled to eat 3 meals/day plus
snacks and to eat until hunger was satisfied. With or with-
out the powdered beverage, the diet was designed to pro-
vide a total glycemic load of not more than 65. In addition
to the diet, subjects in both arms were told to exercise aer-
obically, for a goal of 150 minutes/week, at 50–75% of
maximum heart rate. Individual and target heart rates
were calculated for each subject, and instruction on mon-
itoring heart rates was provided.
Phytochemical tablet description
RIAA from Humulus lupulus L (150 mg/tablet)
For this study, a commercial preparation of the dried RIAA
magnesium salt (Mg-RIAA) provided by John I. Haas
(Yakima, WA) was used. As supplied, this material con-
tained approximately 25% inorganic salts, eg., Mg+2, K+,
and SO4
-2, 5% low-molecular resin and 68% total RIAA.
This RIAA fraction is a well-characterized mixture of
related analogs and diastereomers (Fig. 2) with a ratio of
cis to trans of 3:1 and the ratio of co- to n- of 1:2.2. The
rationale for the magnesium salt form of the extract is that
it provides a free flowing powder allowing for the blend-
ing and tablet manufacture of the finished product.
PAC from Acacia nilotica bark (30 mg/tablet)
Acacia PAC extract was provided by KDN-Vita Interna-
tional/Indfrag Ltd. Due to the manufacturing process, the
extract has a great deal of chemical homogeneity. The
chemical variation relates more to the level of polymeriza-
tion (Fig. 2) than differences in the monomers, which are
mostly catechins and gallates. Generally, an aqueous/
methanol acacia extract consists of approximately 16%
small molecule catechins and gallates, 28% oligomeric
PAC and 56% polymeric PAC.
Measurements
After the baseline visit, subjects returned at 2, 4, 8, and 12
weeks for follow-up visits. At each visit, 3-day diet diaries
(including food choice, amount, time eaten) and 7-day
exercise diaries (including form of exercise, intensity,
duration) were evaluated and subjects were counseled on
compliance to diet and exercise goals. Dietetic food mod-
els (Nasco) were used for accurate estimation of food
intake. Data from 3-day diet diaries were analyzed using
Genesis R&D 6.30 (ESHA Research). Glycemic load was
calculated as described previously [39]. Body weight and
BP were measured at each visit. BP was measured with an
automatic BP monitor (Model HEM-711, Omron Health-
care, Inc.). Waist circumference was measured at the nar-
rowest point between the iliac crest and the lowest rib at
baseline, at 8 weeks, and 12 weeks.
Subjects completed a Food Craving Inventory (Penning-
ton Biomedical Research Center), a Medical Outcome
Study Short Form 36 (a questionnaire to assess the quality
of life) [40], and a satiety questionnaire at each visit. The
Food Craving Inventory listed 28 different foods and
instructed the subject to rate cravings to consume each
particular food over the preceding month [41]. The ques-
tionnaire was scored according to groupings of foods in 4
subscales: high fats, sweets, carbohydrates/starches, and
fast foods. A higher score indicated increased levels of
craving. Satiety was assessed using a 10 cm visual analog
scale in which subjects were asked to assess feelings of
hunger since their last visit at three different times during
the day; a higher score indicated more feelings of hunger.
Individual scores were averaged for overall satiety per sub-
ject. Diet and exercise compliance were assessed at each
visit by one of the investigators. The number of minutes
of aerobic exercise was obtained from each subject's 7-day
Flow chart of participant enrollment and study design Figure 1
Flow chart of participant enrollment and study 
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exercise diary. The Framingham 10-year CVD risk score
was calculated as described previously [42] by using age
and relevant laboratory and questionnaire data for every
individual.
Laboratory analyses
Following an overnight fast, blood samples were collected
from subjects at baseline, 8 weeks, and 12 weeks and
stored at -80°C. Analysis of serum samples was conducted
in batches and, except for lipoprotein subclass analysis,
was performed by Laboratories Northwest. Glucose, lip-
ids, and complete metabolic profiles of serum samples
were assayed using a Vitros 950IRC analyzer (Ortho-Clin-
ical Diagnostics). LDL was determined indirectly using the
Friedewald formula: LDL = total cholesterol – HDL – TG/
5 [43]. Non-HDL was determined by subtracting HDL
from total cholesterol [44]. Apolipoproteins (apo) A-I and
B were analyzed by turbidimetry using an Advia 1650®
(Bayer Diagnostics). Lipoprotein subclass particle analysis
was done with an automated NMR spectroscopic assay by
LipoSciences, Inc. Insulin was determined by a chemilu-
minescent, immunometric assay using the DPC Immulite
2000 (Diagnostics Products Corporation). HbA1c was
quantified on fresh blood samples by ion exchange HPLC
(Bio-Rad Variant II). Complete blood count was done on
fresh blood by standard laboratory methods.
Statistical analysis
Sample size was determined based on the results of an ear-
lier study [37] in which a mean decrease of 0.62 mmol/L
in LDL with the SD of 0.85 mmol/L was reported. Assum-
ing a significance level of 0.05 with the power of 80%, a
sample size of 17 subjects per treatment group was
needed. We recruited more than 34 subjects to account for
possible attrition. The data were analyzed as follows: for
each variable, changes from baseline to 8 weeks and 12
weeks were calculated for each treatment group. Baseline
determinations were analyzed using 2-sided t-tests.
Changes from baseline to 8 weeks and 12 weeks were ana-
lyzed separately for each arm using a priori one-sided
paired t-test. To detect any treatment differences between
the arms, one sided unpaired t-tests were used. Additional
analyses adjusting for calorie intake change, carbohydrate
intake change and body weight loss were performed by
using General Linear Model. Two-sided Wilcoxon signed-
rank analysis was used to determine the significance of
change in MetS score within arms. Missing values were
not imputed for these analyses. Data were reported as
means ± SE and analyzed using SAS (software version 8.1,
SAS Institute). The probability of a type I error was set at
the nominal 5 percent level.
Results
Subjects
The characteristics of subjects at baseline are presented in
Table 1. None of the subjects had been in a weight loss
Structural formula of (A) rho iso-alpha acids from Humulus  lupulus L. and (B) proanthocyanidins from Acacia nilotica bark  extract (N = 4–10 for oligomeric, and > 10 for polymeric  fractions) Figure 2
Structural formula of (A) rho iso-alpha acids from 
Humulus lupulus L. and (B) proanthocyanidins from 
Acacia nilotica bark extract (N = 4–10 for oligomeric, 
and > 10 for polymeric fractions). rho iso-alpha acids for-
mulation contains approximately 25% inorganic salts, eg., 
Mg+2, K+, and SO4
-2, 5% low-molecular resin and 68% total 
rho iso-alpha acids, as a mixture of related analogs and dias-
tereomers with a ratio of cis to trans of 3:1 and a ratio of co- 
to n- of 1:2.2. The aqueous/methanol acacia extract consists 
of approximately 16% small molecule catechins and gallates, 
28% oligomeric proanthocyanidins with a degree of polymer-
ization of 4–8 and 56% polymeric proanthocyanidins with a 
degree of polymerization of 58.Nutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
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program over the preceding 6 weeks. Of the 26 subjects
randomized to the PED arm, 25 completed 8 weeks and
23 completed the trial; of the 23 subjects assigned to the
MED arm, 19 completed 8 weeks and 18 completed the
trial. Among those who did not complete the trial, all but
1 withdrew due to personal issues (e.g. traveling distance);
one subject reported intolerance to the powdered bever-
age. Approximately two-thirds of the subjects (66%) were
women. The average age of the participants was 53 years,
and 82% of the subjects were obese (BMI ≥ 30). Overall,
both arms were well matched with respect to the initial
variables. However, the mean baseline HbA1c was higher
in MED than PED subjects (6.04% vs. 5.70%, P = 0.02).
The complete blood count and complete metabolic pro-
file variables for all subjects remained stable within the
reference ranges (data not shown). One subject in each
arm was accepted outside of study criteria meeting 2
rather than at least 3 components of MetS. Both were
women; one in the MED arm with borderline waist cir-
cumference of 34 inches; the other in the PED arm with
borderline TG 1.63 mmol/L. In addition, at baseline, two
other subjects in the PED arm no longer met MetS criteria.
Caloric and macronutrient intake, study compliance, and 
food craving
No differences between the groups were noted at baseline
in dietary caloric or macronutrient intake (Table 2), and
taking into account supplementation, the glycemic load
did not differ between arms at 8 weeks and 12 weeks. The
total caloric intake and daily fat consumption, especially
the saturated fatty acid, declined in both arms but the dif-
ference between arms at 8 weeks and 12 weeks was not
significant. Monounsaturated fatty acid intake decreased
in both arms compared to their baseline, but the percent
energy from monounsaturated fatty acids remained
unchanged throughout the study (10.0% at baseline and
10.2% at 12 weeks for PED; 10.8% at baseline and 11.2%
at 12 weeks for MED). The carbohydrate intake decreased
in both arms over time. The intake of soluble fiber
increased 5-fold in the PED arm at 8 weeks and 12 weeks
but only 1.5-fold in the MED arm. Daily consumption of
protein by PED subjects increased over time (~16%
increase by 12 weeks) whereas it decreased in the MED
subjects (~13% decrease by 12 weeks). Alcohol consump-
tion declined in both arm but the difference between arms
at 8 weeks and 12 weeks was not significant.
With respect to overall exercise compliance, the two arms
were well matched at baseline, and compliance did not
change over the course of the trial according to evaluation
of the 7-day exercise diaries. Dietary compliance, as eval-
uated by glycemic load, did not differ at either 8 weeks or
12 weeks between groups, and glycemic loads of both
arms were < 65. Compliance for the supplementation in
the PED arm was high, with 93% for the powdered bever-
age and 95% for the phytochemical tablet. Craving for fast
foods was greater at baseline in the MED (P = 0.03) than
the PED arm. Cravings decreased significantly from base-
line for sweets, fast foods, fats, and carbohydrates by 2
weeks and remained significantly reduced in both arms
throughout the 12 weeks of study. There were no statisti-
cal differences between the arms from 2 weeks through 12
weeks. Also, hunger/satiety did not differ at baseline
between the arms. Hunger between the three major meals
(breakfast, lunch, and dinner), and general hunger
throughout the day decreased from baseline to 8 and 12
weeks in subjects on both arms. However, hunger
between the end of the evening meal and retiring
decreased significantly only in the PED arm at both 8 and
12 weeks (-1.88 ± 0.39, P < 0.01, and -1.63 ± 0.47, P <
0.05, respectively), but not in the MED arm (-0.49 ± 0.56
and -0.82 ± 0.57, respectively). No differences between
the arms were noted in quality-of-life questionnaire form
Medical Outcome Study Short Form 36 (data not shown).
Weight loss, waist circumference, and BP
Although this was not designed to be a weight-loss study,
subjects in both arms who completed the 12-week study
lost nearly identical amounts of weight (PED arm, -5.9 ±
0.7 kg; MED arm, -5.7 ± 1.0 kg). Similarly, in both groups,
waist circumference was reduced significantly (P < 0.01)
at 8 and 12 weeks. With regard to BP, subjects in the PED
arm experienced reductions in both systolic and diastolic
BP at the end of the trial; from 129.7 ± 3.5 mm Hg at base-
Table 1: Baseline characteristics of study participants1
PED arm MED arm P value
n2 25 19
Sex
Men 9 6
Women 16 13
Age, year 53.3 ± 2.4 51.7 ± 2.1 0.65
Wt, kg 95.3 ± 3.8 99.6 ± 3.6 0.42
Waist, cm 106.9 ± 2.0 111.6 ± 3.0 0.18
BMI, kg/m2 33.2 ± 0.8 35.2 ± 0.9 0.09
BP, mmHg
Systolic 129.7 ± 3.5 132.8 ± 3.6 0.54
Diastolic 87.0 ± 2.3 85.2 ± 2.0 0.57
Fasting glucose, mmol/L 5.49 ± 0.10 5.63 ± 0.11 0.40
Fasting insulin, pmol/L 82.65 ± 8.33 110.43 ± 13.13 0.07
HbA1c,% 5.7 ± 0.1 6.0 ± 0.1 0.02
Cholesterol, mmol/L 6.57 ± 0.15 6.67 ± 0.20 0.71
LDL, mmol/L 4.39 ± 0.173 4.64 ± 0.204 0.34
TG, mmol/L 2.78 ± 0.22 2.37 ± 0.23 0.21
HDL, mmol/L 0.98 ± 0.05 1.02 ± 0.05 0.65
TG/HDL 3.07 ± 1.7 2.50 ± 1.4 0.23
1Values for continuous variables are means ± SE
2Subjects completing at least 8 weeks of study
3Data from 23 subjects
4Data from 17 subjectsNutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
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line to 123.4 ± 2.7 mm Hg at 12 weeks for systolic BP (P
= 0.025); and from 87.0 ± 2.3 mm Hg at baseline to 82.0
± 2.0 mm Hg at 12 weeks for diastolic BP (P = 0.005). Sub-
jects in the MED arm, on the other hand, displayed a
decline only in systolic BP (132.8 ± 3.6 mm Hg at baseline
to 128.1 ± 1.8 mm Hg at 12 weeks, P = 0.03); their diasto-
lic BP remained unchanged throughout the study (85.2 ±
2.0 mm Hg at baseline to 84.4 ± 1.6 mm Hg).
Serum lipids and apolipoproteins
Effects of intervention diets on cardiometabolic risk vari-
ables are summarized in Table 3 and individual responses
are illustrated in Fig. 3. Subjects in both arms experienced
reductions in total cholesterol, LDL, non-HDL choles-
terol, and cholesterol/HDL at 8 weeks and 12 weeks of the
trial. The decrease in total cholesterol and non-HDL cho-
lesterol from baseline to 12 weeks was greater in the PED
than in the MED arm (P = 0.03 and 0.02, respectively): the
average percent reduction in total cholesterol was 14.5%
in the PED arm but only 6.3% in the MED arm and in
non-HDL cholesterol was 18.2% in the PED arm but only
8.0% in the MED arm. The decrease in cholesterol/HDL
was greater in the PED than in the MED arm (P = 0.01).
With regard to serum TG and TG/HDL, a recognized
marker of MetS, subjects in both arms experienced reduc-
tions at 8 weeks. However, only subjects in the PED arm
continued to exhibit decreases in serum TG and TG/HDL
at 12 weeks; the difference between the 2 arms was signif-
icant at 12 weeks (P = 0.03 and 0.02, respectively). There
was an average 42.7% reduction in TG/HDL in the PED
arm and only a 17.6% decrease in the MED arm. Serum
HDL increased from baseline to 12 weeks only in subjects
on the PED arm (P < 0.05), and remained unchanged in
the MED arm. Compared to baseline, the total LDL parti-
cle number decreased in the PED arm at 8 and 12 weeks,
and in the MED arm only at 12 weeks. VLDL particle
number decreased at both 8 and 12 weeks only in the PED
arm; large HDL particle number increased in both arms at
8 and 12 weeks (data not shown). With respect to lipopro-
tein variables, both PED and MED arms showed reduction
of apo B concentration and apo B/apo A-I at 8 weeks com-
pared to baseline; however, only the PED arm exhibited
continued reduction in both variables from 8 weeks to 12
weeks. Additional adjustment for calorie and carbohy-
Table 2: Caloric and nutrient intake at baseline, 8 weeks and 12 weeks
Nutrient Visit PED arm1 MED arm2 P value (between arms)
mean ± SE
Total energy (kJ/d) Baseline 9654 ± 571 11575 ± 1619 0.22
8 weeks 6699 ± 370 6171 ± 479 0.38
12 weeks 6442 ± 285 5835 ± 472 0.25
Carbohydrates (g/d) Baseline 261.7 ± 19.0 337.9 ± 45.8 0.10
8 weeks 188.9 ± 10.9 150.9 ± 13.8 0.03
12 weeks 169.6 ± 9.3 151.4 ± 13.6 0.22
Insoluble fiber (g/d) Baseline 6.0 ± 0.7 4.3 ± 0.6 0.09
8 weeks 10.4 ± 1.3 8.1 ± 1.0 0.17
12 weeks 9.4 ± 1.0 8.3 ± 1.4 0.51
Soluble fiber (g/d) Baseline 2.3 ± 0.3 2.1 ± 0.3 0.58
8 weeks 11.8 ± 0.5 3.1 ± 0.4 < 0.01
12 weeks 11.5 ± 0.3 3.3 ± 0.5 < 0.01
Protein (g/d) Baseline 100.2 ± 7.0 97.7 ± 13.0 0.86
8 weeks 112.5 ± 6.1 90.7 ± 7.2 0.03
12 weeks 116.1 ± 7.6 85.3 ± 7.9 0.01
Fat (g/d) Baseline 96.2 ± 7.4 113.5 ± 17.1 0.32
8 weeks 47.6 ± 3.7 59.5 ± 5.18 0.06
12 weeks 46.8 ± 4.7 52.7 ± 5.19 0.40
Saturated fatty acid (g/d) Baseline 30.5 ± 2.9 35.0 ± 4.5 0.39
8 weeks 10.5 ± 0.9 14.0 ± 1.7 0.05
12 weeks 10.1 ± 1.1 12.8 ± 1.3 0.11
Monounsaturated fatty acid (g/d) Baseline 25.6 ± 3.1 33.1 ± 5.5 0.21
8 weeks 14.8 ± 1.5 19.7 ± 1.7 0.04
12 weeks 17.4 ± 2.2 17.4 ± 2.3 0.98
Cholesterol (mmol/d) Baseline 9.48 ± 0.96 9.22 ± 1.10 0.86
8 weeks 6.31 ± 0.69 10.01 ± 1.38 0.01
12 weeks 6.79 ± 0.94 8.33 ± 1.03 0.34
Alcohol (g/d) Baseline 4.9 ± 1.4 3.3 ± 2.3 0.56
8 weeks 1.2 ± 0.8 3.1 ± 1.2 0.19
12 weeks 1.6 ± 0.9 2.1 ± 1.3 0.75
1PED arm: Baseline & 8 weeks, n = 25; 12 weeks, n = 23. 2MED arm: Baseline & 8 weeks, n = 19; 12 weeks, n = 18.Nutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
Page 8 of 14
(page number not for citation purposes)
drate intake, and body weight change for these variables
did not change the findings (adjusted P values in Table 3).
Glucose, insulin, HbA1c, and HOMA score
Subjects in both arms exhibited decrease in fasting insulin
concentrations and HbA1c at 8 and 12 weeks comparing
to baseline (Table 3). With respect to fasting glucose, only
subjects in the MED arm displayed reduction from base-
line at 12 weeks. A reduction in HOMA score was
observed in PED arm at both 8 weeks and 12 weeks, but
in MED arm only at 8 weeks. No differences between arms
were observed with respect to fasting insulin, fasting glu-
cose, HOMA score, and HbA1c at both 8 and 12 weeks.
Additional adjustment for calorie and carbohydrate
intake, and body weight change for these variables did not
change the findings (adjusted P values in Table 3).
Metabolic syndrome variables and Framingham 10-year 
CVD risk score
At baseline, 23 subjects in the PED arm and 22 subjects in
the MED arm met at least 3 of 5 criteria for MetS. The
mean number of MetS criteria for the PED arm including
only those subjects with MetS at baseline and only those
completing 12 weeks was 3.81 ± 0.18 (n = 21), and 4.17
± 0.19 (n = 18) for the MED arm. After 12 weeks on the
trial, the number of MetS variables reduced to 2.95 ± 0.26
in the PED arm (P = 0.01), and to 3.56 ± 0.28 in the MED
arm (P = 0.07). At the end of 12 weeks, 9 of the 21 subjects
(43%) in PED arm no longer met criteria for MetS com-
pared with only 4 of the 18 subjects (22%) in the MED
arm. The calculated Framingham 10-year CVD risk score
in subjects finishing all visits of the trial fell from 15.3 ±
2.5% at baseline to 9.6 ± 1.4% at 12 weeks in the PED arm
(P < 0.001), and from 16.0 ± 3.0% at baseline to 13.1 ±
2.7% at 12 weeks for the MED arm (P = 0.011).
Discussion
Due to the complex mechanistic underpinnings of MetS,
strategies for reducing its incidence and consequences
need to be similarly comprehensive and multi-factorial.
Targeting multiple, chronically dysregulated signaling
pathways at play in insulin resistance is likely to yield the
greatest benefit [45] in the treatment of MetS. To our
knowledge, this is the first intervention study to success-
fully demonstrate the concept of modifying cardiometa-
bolic risk factors by combining a modified
Mediterranean-style, low glycemic load dietary pattern,
and regular exercise, with diverse phytochemicals target-
ing multiple signaling abnormalities of MetS. A greater
than 2-fold improvement in total cholesterol, non-HDL
cholesterol, TG, cholesterol/HDL, and TG/HDL were
observed with the addition of soy protein, phytosterols,
hops RIAA, and acacia PAC to a modified Mediterranean-
style low glycemic load diet and exercise program.
Increase in HDL and decrease in LDL and VLDL particle
numbers were seen only in the PED arm. Also, diastolic
BP fell only in the PED arm. Furthermore, by 12 weeks,
almost double the number of subjects experienced a net
resolution of MetS in the PED group compared with MED
group, and the PED group experienced almost twice the
reduction in the Framingham 10-year CVD risk score as
the MED group. Overall, CVD risk was reduced to a greater
degree in the subjects supplemented with phytochemicals
relative to the subjects on MED alone.
Previously [37], we compared a calorically-restricted ver-
sion of the diet used in this study supplemented with soy
protein and phytosterols to the frequently-studied AHA
Step I low-fat diet in postmenopausal hypercholestero-
lemic women. We demonstrated that this targeted phyto-
chemical, supplemented diet produced greater benefits
than the AHA diet alone. The protocol for the current trial
differed from that of our previous study in 2 key aspects:
(i) subjects in both study arms were instructed to con-
sume their diet until satisfied, and (ii) 2 additional sup-
plemental phytochemicals were provided to target the
underlying inflammatory mechanisms of MetS. The mod-
ified Mediterranean-style, low glycemic load diet by itself
is an effective approach to weight loss and CVD risk reduc-
tion [46]. Our findings suggest that the addition of the soy
protein, phytosterols, in combination with targeted phy-
tochemicals was responsible for the more favorable CVD
risk profile outcome in the PED group. This observation
could not be attributed to greater weight loss in the PED
group, since the extent of weight loss was similar on both
arms. A recent review by Volek and Feinman reported that
dietary carbohydrate may affect various cardiometabolic
factors [10]. In our analysis, we adjusted for calorie and
carbohydrate intake, and body weight change, and found
that the observed differences between arms remained
unaffected (Table 3). Likewise, the glycemic loads of the
diets and the levels of exercise did not differ between
arms. Although provision of the powdered beverage may
have simplified meal planning, and in turn, enhanced die-
tary compliance and convenience, an effect similar to that
reported by Noakes et al. [47], again weight loss did not
differ. Finally, although only subjects in the PED arm
experienced a decrease in hunger levels in the period
between the evening meal and bedtime, which might
have reduced excessive, nighttime snacking, differences in
intake should have been reflected in differential body
weight loss and recorded caloric intake, neither of which
occurred.
RIAA is a modified hop extract that has been used in beer
for flavoring, foam stability and bittering for decades, and
is prized for its chemical stability. RIAA is derived from
hop cones in a process that first involves extraction of
whole hops with supercritical CO2, yielding an extract
containing a mixture of alpha acids, beta acids and hopNutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
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Table 3: Effect of intervention diets on cardiovascular risk variables at baseline, 8 weeks and 12 weeks of intervention
Variable Visit PED arm MED arm P value2 
(Difference 
between arm)
Adjusted P 
value3
Value (mean ± SE) Mean % change 
from baseline
Value (mean ± SE) Mean % change 
from baseline
Cholesterol (mmol/L) Baseline 6.57 ± 0.15 6.67 ± 0.20
8 weeks 5.67 ± 0.22** -13.8% 6.09 ± 0.25** -8.7% 0.13 0.04
12 weeks 5.59 ± 0.14** -14.5% 6.27 ± 0.22* -6.3% 0.03 0.04
TG (mmol/L) Baseline 2.78 ± 0.22 2.37 ± 0.23
8 weeks 2.02 ± 0.25** -27.2% 1.84 ± 0.17** -22.3% 0.27 0.05
12 weeks 1.86 ± 0.12** -35.2% 2.09 ± 0.19 -14.3% 0.03 0.01
HDL (mmol/L) Baseline 0.98 ± 0.05 1.02 ± 0.05
8 weeks 0.99 ± 0.05 0.7% 1.00 ± 0.04 -1.6% 0.34 0.45
12 weeks 1.05 ± 0.05* 7.0% 1.04 ± 0.05 2.7% 0.18 0.21
LDL (mmol/L) Baseline 4.39 ± 0.17 4.64 ± 0.20
8 weeks 3.78 ± 0.19** -16.8% 4.24 ± 0.20** -9.8% 0.11 0.19
12 weeks 3.69 ± 0.12** -17.3% 4.28 ± 0.17* -8.4% 0.11 0.18
Non-HDL 
cholesterol (mmol/L)
Baseline 5.59 ± 0.14 5.65 ± 0.19
8 weeks 4.67 ± 0.20** -16.4% 5.09 ± 0.25** 10.0% 0.19 0.03
12 weeks 4.54 ± 0.14** -18.2% 5.23 ± 0.22* -8.0% 0.02 0.03
LDL particle number 
(nmol/L)
Baseline 1634 ± 57 1733 ± 84
8 weeks 1453 ± 63* -11.9% 1618 ± 108 -6.6% 0.24 0.19
12 weeks 1455 ± 63* -11.9% 1629 ± 109* -7.0% 0.26 0.31
Chol/HDL Baseline 6.9 ± 0.3 6.8 ± 0.3
8 weeks 5.9 ± 0.3** -14.3% 6.2 ± 0.3** -9.0% 0.13 0.09
12 weeks 5.6 ± 0.3** -19.5% 6.3 ± 0.4** -8.9% 0.01 0.02
TG/HDL Baseline 3.1 ± 1.7 2.5 ± 1.4
8 weeks 2.1 ± 1.3** -30.6% 1.9 ± 0.9** -23.2% 0.20 0.07
12 weeks 1.9 ± 0.7** -42.7% 2.1 ± 1.1 -17.6% 0.02 0.01
apo A-I (g/L) Baseline 1.94 ± 0.06 1.96 ± 0.07
8 weeks 1.89 ± 0.05 -2.5% 1.88 ± 0.06 -3.9% 0.32 0.30
12 weeks 1.90 ± 0.06 -2.1% 1.87 ± 0.06 -4.3% 0.24 0.16
apo B (g/L) Baseline 1.48 ± 0.05 1.50 ± 0.06
8 weeks 1.30 ± 0.05** -12.1% 1.36 ± 0.06** -9.9% 0.32 0.21
12 weeks 1.21 ± 0.04** -17.5% 1.36 ± 0.06** -9.9% 0.09 0.14
apoB/apoA-I Baseline 0.78 ± 0.03 0.78 ± 0.04
8 weeks 0.70 ± 0.03* -10.3% 0.73 ± 0.04* -6.4% 0.26 0.13
12 weeks 0.66 ± 0.03** -15.4% 0.75 ± 0.05* -6.3% 0.07 0.08
Fasting Glucose 
(mmol/L)
Baseline 5.49 ± 0.10 5.63 ± 0.11
8 weeks 5.31 ± 0.11 -3.3% 5.46 ± 0.10 -2.9% 0.45 0.42
12 weeks 5.39 ± 0.10 -2.2% 5.41 ± 0.12* -4.8% 0.85 0.92
Fasting Insulin (pmol/
L)
Baseline 82.65 ± 8.33 110.43 ± 13.13
8 weeks 53.48 ± 4.58** -35.2% 75.70 ± 10.42* -31.0% 0.66 0.82
12 weeks 60.42 ± 5.69** -26.8% 88.90 ± 11.74* -22.3% 0.59 0.74
HOMA1 Baseline 3.0 ± 0.4 4.1 ± 0.6
8 weeks 1.8 ± 0.2** -38.9% 2.7 ± 0.4* -32.6% 0.63 0.81
12 weeks 2.0 ± 0.2* -29.7% 3.0 ± 0.5 -24.9% 0.61 0.76
HbA1c % Baseline 5.7 ± 0.1 6.0 ± 0.1
8 weeks 5.6 ± 0.1* -1.9% 5.9 ± 0.1** -2.7% 0.77 0.72
12 weeks 5.6 ± 0.1** -2.6% 5.8 ± 0.1** -3.8% 0.82 0.87
*Different from baseline, P < 0.05
**Different from baseline, P < 0.01
1HOMA score calculated as follows: [(insulin (pmol/L)*glucose (mmol/L))/135].
2Comparing the values between arms using 1-sided unpaired t-test
3Adjusted for body weight, caloric intake, and carbohydrate intakeNutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
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oils [48,49]. The alpha acids are differentially isolated,
isomerized, and reduced to form RIAA. The Acacia nilotica
tree grows naturally in many arid climates in Australia,
Africa, and India and the young trees are a food source for
many animals including cattle [50-52]. The young leaves
have been fried and consumed like other leafy vegetables.
The bark is ingested traditionally as a hot beverage and in
a more concentrated form as a folk medicine for various
ailments including colds, diarrhea, tuberculosis and lep-
rosy [53]. The rationale for inclusion of the RIAA/PAC tab-
let was based on results of in vitro screening studies
employing insulin resistant 3T3-L1 adipocytes, db/db
mouse diabetes studies, and a pilot clinical trial (unpub-
lished results); all consistently showing improvement in
insulin sensitivity. Briefly, the RIAA/PAC combination
displayed lipogenic and anti-inflammatory activity in
murine 3T3-L1 adipocytes stimulated with TNFα. Both
agents inhibited TNFα-stimulated IL-6 secretion and
improved adiponectin secretion. Individually and in vari-
ous combinations these compounds also demonstrated
favorable modulation of the activity of proteins and
kinases implicated in insulin signaling such as PI3K, GSK-
3, AKT, PKC and c-Jun N-terminal kinase (manuscript in
preparation). Other groups have reported that feeding of
isohumulone, which is structurally similar to RIAA, to
C57BL/6N mice reduced plasma TG and free fatty acid lev-
els [54]. Additional animal and clinical studies with iso-
humulone have revealed that: (i) diabetic KK-Ay mice had
reduced plasma glucose, TG, and free fatty acid levels,
65.3, 62.6, and 73.1%, respectively; (ii) C57BL/6N mice
fed a high fat diet showed improved glucose tolerance and
reduced insulin resistance; and (iii) a double-blind, pla-
cebo-controlled pilot study on diabetic subjects suggested
that isohumulones decreased blood glucose and HbA1c
levels by 10.1 and 6.4%, respectively, after 8 weeks [55].
We chose RIAA over IAA due to RIAA's greater chemical
stability [48], potent in vitro anti-inflammatory activity in
3T3-L1 adipocytes. In our pilot clinical trial a combina-
tion of RIAA and PAC in tablet form significantly
improved LDL, TG and TG/HDL in subjects with MetS.
The results of the present study, in agreement with similar
studies reported by others [25-28], confirm the benefits of
lifestyle intervention consisting of a phytochemical rich,
low glycemic load diet and a moderate aerobic exercise
regimen in subjects with MetS. For example, Jenkins et al.
[56] found reductions in lipid variables with an ad libitum
low glycemic load diet ("portfolio diet") in subjects with
high TG at baseline. The average reductions reported by
Jenkins et al. in total cholesterol, LDL and TG over one
month were almost identical to those noted in the MED
arm of the present study over 8 weeks (8.8% vs. 8.7%;
9.1% vs. 9.8%; and 19.3% vs. 22.3%, respectively). Also,
similar to the results reported by Jenkins et al. [56], no
changes in HDL were noted in MED subjects in the
present study. Lastly, in both arms of the present trial, we
found that subjects' food cravings fell and satiety
increased with institution of the low glycemic load diet
and energy intake fell despite the lack of instructions to
limit caloric intake. Esposito et al. reported that 48% of
subjects with MetS instructed to follow a Mediterranean-
style (not necessarily low glycemic) diet over 2 years no
longer met 3 or more criteria for MetS [57]. In the Diabe-
tes Prevention Program Trial, lifestyle modification led to
38% resolution of MetS after 3 years [58]. In contrast, only
minimal resolution of MetS was seen in the Diabetes Pre-
vention Program Trial after one year with either met-
formin or lifestyle management [58]. Our study suggests
that by complementing a therapeutic lifestyle program
with a soy- and phytosterol-based powdered beverage and
tablets containing hops RIAA and acacia PAC, subjects can
improve to a similar magnitude (43%) attained at 2 and 3
years in just 12 weeks.
Most therapeutic treatments for hypercholesterolemia
focus on achieving LDL goals recommended by NCEP.
However, the NHANES 2003–2004 showed that despite
better control of LDL, other lipid risk factors remained
suboptimal in many US adults, particularly among those
with CVD, diabetes, or MetS [59]. Non-HDL cholesterol,
a stronger predictor of CVD and mortality risk than LDL
[60-62], has now been added by the NCEP Adult Treat-
ment Panel III as a secondary target of therapy [63]. In
addition, because apo B indicates the total number of
atherogenic lipoprotein particles and apo A-I, a major
lipoprotein in HDL, has a critical role in reverse choles-
terol transport, the apo B/apo A-I (as well as apo B con-
centration) has been proposed as a risk factor for CVD.
Increasing evidence from multiple studies has repeatedly
shown that the apo B/apo A-I predicts cardiovascular risk
– the lower the ratio, the lower is the risk – and is a better
marker than LDL and lipid ratios [64-71]. In the Inter-
Heart study, the apo B/apo A-I was the strongest determi-
nant of MI risk, even higher than smoking; the OR of top
vs. lowest decile was 4.73 [72]. The authors state the apo
B/apo A-I might be the best marker of the balance of
atherogenic and antiatherogenic particles. Subjects in
both PED and MED arms showed significant reduction in
non-HDL cholesterol and apo B/apo A-I at 8 weeks com-
pared to baseline, but only the PED arm showed contin-
ued reduction in the ratio at 12 weeks. These data suggest
further cardiovascular benefit from the added phytochem-
icals.
Conclusion
The worldwide prevalence and multi-factorial nature of
MetS do not reasonably support a pharmacologic
approach for treatment or prevention. Fortunately, life-
style modification including dietary alteration has dem-
onstrated success in correcting metabolic abnormalitiesNutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
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Individual responses in serum lipid parameters (A, total cholesterol; B, LDL; C, HDL; D, non-HDL cholesterol; E, TG; F, TG/ HDL; G, LDL particle number; H, apo B/apo A-I) in the intervention (PED) and control (MED) arms at baseline and 12 weeks Figure 3
Individual responses in serum lipid parameters (A, total cholesterol; B, LDL; C, HDL; D, non-HDL cholesterol; 
E, TG; F, TG/HDL; G, LDL particle number; H, apo B/apo A-I) in the intervention (PED) and control (MED) 
arms at baseline and 12 weeks. Shaded bars indicate mean responses.Nutrition & Metabolism 2008, 5:29 http://www.nutritionandmetabolism.com/content/5/1/29
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associated with the development of type 2 diabetes and
CVD. The present study provides evidence that supple-
mentation of a modified Mediterranean-style, low glyc-
emic load diet with a combination of phytochemicals
addressing multiple inflammatory and insulin signaling
pathways simultaneously may be a novel, effective means
to managing MetS. This comprehensive, supplemented
lifestyle program represents a potentially powerful
approach to the management of at risk individuals with
MetS and hypercholesterolemia.
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